Literature DB >> 22409425

Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting.

Lin Zhu1, Pooja Kate, Vladimir P Torchilin.   

Abstract

A novel "smart" multifunctional drug delivery system was successfully developed to respond to the up-regulated matrix metalloprotease 2 (MMP2) in the tumor microenvironment and improve cancer cell-specific delivery of loaded drugs. The system represents a surface-functionalized liposomal nanocarrier, for which two functional polyethylene glycol (PEG)-lipid conjugates were synthesized and characterized. The functionalized liposome was further modified with the tumor cell-specific antinucleosome monoclonal antibody (mAb 2C5). In the resulting system, several drug delivery strategies were combined in the same nanocarrier in a simple way and coordinated in an optimal fashion. The functions of the nanocarrier include (i) the hydrophilic and flexible long PEG chains to prevent nanocarrier nonspecific interactions and prolong its circulation time; (ii) a nanoscale size of the system that allows for its passive tumor targeting via the enhanced permeability and retention (EPR) effect; (iii) a mAb 2C5 to allow for the specific targeting of tumor cells; (iv) a matrix metalloprotease 2-sensitive bond between PEG and lipid that undergoes cleavage in the tumor by the highly expressed extracellular MMP2 for the removal of PEG chains; (v) cell-penetrating peptide (TATp) triggering of the enhanced intracellular delivery of the system after long-chain PEG removal and exposure of the previously hidden surface-attached TATp. It is shown that such a design can enhance the targetability and internalization of nanocarriers in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22409425      PMCID: PMC3337349          DOI: 10.1021/nn300524f

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  30 in total

1.  Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier.

Authors:  P M Friden; L R Walus; G F Musso; M A Taylor; B Malfroy; R M Starzyk
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

Review 2.  RGD and other recognition sequences for integrins.

Authors:  E Ruoslahti
Journal:  Annu Rev Cell Dev Biol       Date:  1996       Impact factor: 13.827

3.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes.

Authors:  A L Klibanov; K Maruyama; V P Torchilin; L Huang
Journal:  FEBS Lett       Date:  1990-07-30       Impact factor: 4.124

4.  Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target.

Authors:  A L Klibanov; K Maruyama; A M Beckerleg; V P Torchilin; L Huang
Journal:  Biochim Biophys Acta       Date:  1991-02-25

5.  A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice.

Authors:  L Z Iakoubov; V P Torchilin
Journal:  Oncol Res       Date:  1997       Impact factor: 5.574

6.  Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody.

Authors:  Anatoly N Lukyanov; Tamer A Elbayoumi; Ananthsrinivas R Chakilam; Vladimir P Torchilin
Journal:  J Control Release       Date:  2004-11-05       Impact factor: 9.776

7.  Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits.

Authors:  V D Awasthi; D Garcia; B A Goins; W T Phillips
Journal:  Int J Pharm       Date:  2003-03-06       Impact factor: 5.875

8.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.

Authors:  F Yuan; M Dellian; D Fukumura; M Leunig; D A Berk; V P Torchilin; R K Jain
Journal:  Cancer Res       Date:  1995-09-01       Impact factor: 12.701

9.  PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles.

Authors:  Swaroop Mishra; Paul Webster; Mark E Davis
Journal:  Eur J Cell Biol       Date:  2004-04       Impact factor: 4.492

10.  A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2.

Authors:  Ahmed M Mansour; Joachim Drevs; Norbert Esser; Farid M Hamada; Osama A Badary; Clemens Unger; Iduna Fichtner; Felix Kratz
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

View more
  82 in total

1.  Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNA-34a Co-Delivery Triggered by Dual Stimuli in Tumor Tissue.

Authors:  Giuseppina Salzano; Daniel F Costa; Can Sarisozen; Ed Luther; George Mattheolabakis; Pooja P Dhargalkar; Vladimir P Torchilin
Journal:  Small       Date:  2016-07-19       Impact factor: 13.281

Review 2.  Stimuli-responsive nanocarriers for drug delivery.

Authors:  Simona Mura; Julien Nicolas; Patrick Couvreur
Journal:  Nat Mater       Date:  2013-11       Impact factor: 43.841

3.  Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications.

Authors:  Parham Sahandi Zangabad; Soroush Mirkiani; Shayan Shahsavari; Behrad Masoudi; Maryam Masroor; Hamid Hamed; Zahra Jafari; Yasamin Davatgaran Taghipour; Hura Hashemi; Mahdi Karimi; Michael R Hamblin
Journal:  Nanotechnol Rev       Date:  2017-12-12       Impact factor: 7.848

Review 4.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

5.  Non-Covalent Assembly Method that Simultaneously Endows a Liposome Surface with Targeting Ligands, Protective PEG Chains, and Deep-Red Fluorescence Reporter Groups.

Authors:  Scott K Shaw; Wenqi Liu; Seamus P Brennan; María de Lourdes Betancourt-Mendiola; Bradley D Smith
Journal:  Chemistry       Date:  2017-08-09       Impact factor: 5.236

6.  Investigating the Cellular Specificity in Tumors of a Surface-Converting Nanoparticle by Multimodal Imaging.

Authors:  Francois Fay; Line Hansen; Stefanie J C G Hectors; Brenda L Sanchez-Gaytan; Yiming Zhao; Jun Tang; Jazz Munitz; Amr Alaarg; Mounia S Braza; Anita Gianella; Stuart A Aaronson; Thomas Reiner; Jørgen Kjems; Robert Langer; Freek J M Hoeben; Henk M Janssen; Claudia Calcagno; Gustav J Strijkers; Zahi A Fayad; Carlos Pérez-Medina; Willem J M Mulder
Journal:  Bioconjug Chem       Date:  2017-05-05       Impact factor: 4.774

7.  Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.

Authors:  Xuelei Yin; Yingying Chi; Chuanyou Guo; Shuaishuai Feng; Jinhu Liu; Kaoxiang Sun; Zimei Wu
Journal:  Pharm Res       Date:  2017-07-19       Impact factor: 4.200

8.  Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs.

Authors:  Lin Zhu; Federico Perche; Tao Wang; Vladimir P Torchilin
Journal:  Biomaterials       Date:  2014-02-13       Impact factor: 12.479

9.  Acid-responsive nanospheres from an asparagine-derived amphiphile.

Authors:  Adelphe M Mfuh; Mathew P D Mahindaratne; Audrey E Yñigez-Gutierrez; Juan R Ramos Dominguez; Jefferson T Bedell; Carlos D Garcia; George R Negrete
Journal:  RSC Adv       Date:  2015       Impact factor: 3.361

Review 10.  Smart nanoparticles improve therapy for drug-resistant tumors by overcoming pathophysiological barriers.

Authors:  Jian-Ping Liu; Ting-Ting Wang; Dang-Ge Wang; An-Jie Dong; Ya-Ping Li; Hai-Jun Yu
Journal:  Acta Pharmacol Sin       Date:  2016-08-29       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.